C4 Therapeutics, Inc.

C4 Therapeutics, Inc. (CCCC) priced its initial public offering on Oct 2, 2020 at $19.00 per share, above its $16.00–$18.00 range, raising $182.4M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $789.4M. Jefferies was lead-left underwriter, joined by Evercore ISI, BMO Capital Markets and UBS. Goodwin Procter advised the company and Cooley advised the underwriters.

C4 Therapeutics, Inc. is a biopharmaceutical company developing small molecule protein degraders that destroy disease-causing proteins for cancer, neurodegenerative conditions and other diseases. Its TORPEDO platform designs degraders focused on catalytic degradation, including against targets previously considered undruggable.

Status

IPO

Ticker

CCCC

Exchange

Nasdaq Global Market

Priced

Oct 2, 2020

IPO price

$19.00

Price range

$16.00–$18.00

Raised

$182.4M

Market cap at IPO price

$789.4M

First filed

Sep 10, 2020

Underwriters

Jefferies, Evercore ISI, BMO Capital Markets and UBS

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.